Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

(Corrects paragraph 15 to reflect that Hims & Hers is one of the most volume-producing of Novo’s partners, and not the most ...

A Fool since 2019, and a graduate of Cal State LA with a B.S. in Finance and M.A. in Economics. Parkev is an adjunct ...

The FDA staff’s view clashes with RFK Jr.’s push to deregulate peptides and move more of them toward Category 1 status.

Hims & Hers' stock rebounded from below $14 after a regulatory shock and is now trading above $37 on a diversified growth narrative. Click to learn more.

Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...

Barclays expects accelerating revenue and EBITDA growth in the second half of 2026, supported by weight-loss offerings.

Dudum also expressed interest in Garmin integration, saying company teams are actively exploring the feature.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best ...

Indian American specialist to guide wellness platform’s expansion of its preventive care and longevity offerings for men.

GLP-1 drugs for weight loss said they planned to drop the drugs in 2027, according to the Business Group on Health (AFP via ) ...